Strategic Sell Setup for Lupin: Precision Trading with Defined RIn this Lupin sell trade setup , we are employing a systematic approach that ensures we trade based on a clear structure:
Identifying Key Levels:
The first step is to recognize a candle that has closed above the all-time high. This candle is crucial as it marks a potential exhaustion point or a possible reversal zone.
Confirmation with Consecutive Candles:
After spotting the all-time high candle, we need to confirm the market's bearish movement. The next two consecutive candles should close below each other, signaling that resistance is strong and the stock price is likely to move down.
Establishing Resistance:
The third key point is the confirmation of resistance. The downward pattern in candle closings suggests that selling pressure is increasing and resistance is solidifying. This signals a good opportunity to plan the trade.
Executing the Trade:
Finally, execute the sell trade based on the rules set in the strategy. This includes placing a stop-loss (27.65) and targeting a reward-to-risk ratio of at least 5:1. In this case, the target is 138.50 with an impressive reward-to-risk ratio of 5.01, ensuring the trade offers substantial profit potential compared to the risk.
This setup not only provides a clear structure for entry but also incorporates a solid risk management plan, making it a robust strategy for traders looking to capitalize on short opportunities in Lupin.
LUPIN
Lupin can take a leap.Lupin Ltd. is an innovation led transnational pharmaceutical company, which engages in the business of producing, developing, and marketing a wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The Company has significant player in the Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporin segments.
Lupin Ltd. CMP is 1621.35. The positive aspects of the company are Company with Low Debt, Annual Net Profits improving for last 2 years, Company with Zero Promoter Pledge, FII / FPI or Institutions increasing their shareholding and Efficient in managing Assets to generate Profits. The Negative aspects of the company are Declining Net Cash Flow : Companies not able to generate net cash, MFs decreased their shareholding last quarter and Promoter decreasing their shareholding.
Entry can be taken after closing above 1636. Targets in the stock will be 1657 and 1677. The long-term target in the stock will be 1700 and 1728. Stop loss in the stock should be maintained at Closing below 1545 or 1497 depending on your risk taking ability.
The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
CNXPHARMA - Trend Reversal 📊 Script: CNXPHARMA (NIFTY PHARMA)
Key highlights: 💡⚡
📈 Nifty Pharma is retesting from its support level shown in chart.
📈 Pharma stocks can give good returns.
📈 One can go for Swing Trade into Pharma stocks.
📊 Script: CIPLA
⏱️ C.M.P 📑💰- 1414
🟢 Target 🎯🏆 - 1510
📊 Script: LUPIN
⏱️ C.M.P 📑💰- 1688
ONLY ABOVE 1700
🟢 Target 🎯🏆 - 1828
📊 Script: AUROPHARMA
⏱️ C.M.P 📑💰- 1177
🟢 Target 🎯🏆 - 1267
📊 Script: GLAND
⏱️ C.M.P 📑💰- 1177
🟢 Target 🎯🏆 - 1267
📊 Script: BIOCON
⏱️ C.M.P 📑💰- 1177
🟢 Target 🎯🏆 - 1267
⚠️ Important: Always maintain your Risk & Reward Ratio.
✅Like and follow to never miss a new idea!✅
Disclaimer: I am not SEBI Registered Advisor. My posts are purely for training and educational purposes.
Eat🍜 Sleep😴 TradingView📈 Repeat 🔁
Happy learning with trading. Cheers!🥂
#THYROCARE 583 recommended to buy - #stockstowatch Rachit SethiaNSE:THYROCARE
THYROCARE 583
TGT 680
SL 540
Return 16%
TF <6M
RR >2
Factors: BULLISH WEDGE BREAKOUT Trend Following Rising Volume with rising Prices. Flag pattern breakout. Pennant Pattern Breakout with Bullish Candle. Retest Successful. Higher Highs & Higher Lows. Broken above RESISTANCE levels Trading at SUPPORT levels Earnings are strong. Bullish Wedge Breakout Risk Return Ratio is healthy. And Rising from Double Bottom Pattern to Flag Pattern forming. If you like my work KINDLY LIKE SHARE & FOLLOW this page for free Stock Recommendations. With 💚 from Rachit Sethia
#JUBLPHARMA 435 TGT 590 SL 400 Buy Recommended - Rachit SethiaJUBLPHARMA 435
Target 590
SL 400
Return 43%
RR > 4.5
TF < 6 Months
Factors: BULLISH WEDGE BREAKOUT Trend Following Rising Volume with rising Prices. Flag pattern breakout. Pennant Pattern Breakout with Bullish Candle. Retest Successful. Higher Highs & Higher Lows. Broken above RESISTANCE levels Trading at SUPPORT levels Earnings are strong. Bullish Wedge Breakout Risk Return Ratio is healthy. And Rising from Double Bottom Pattern to Flag Pattern forming. If you like my work KINDLY LIKE SHARE & FOLLOW this page for free Stock Recommendations. With 💚 from Rachit Sethia
📈 Navigating Lupin: Seizing the 75-Minute Demand Zone!Embark on a strategic journey through Lupin's charts, revealing a promising trade opportunity in simple terms suitable for traders of all levels.
Current Market Position 📊:
LTF (75 min): Lupin is firmly situated within the 75-minute demand zone, specifically at the bottom and exhibiting a very inside structure.
ITF (Daily): Confirming the bullish sentiment, Lupin is comfortably nestled in the daily demand zone, signalling a favourable environment.
HTF (Weekly): On the weekly chart, supply zone is very far, and price is trading at fair location, providing a conducive backdrop for potential upward movements.
Trade Strategy 📈:
Entry: Plan a buy entry at the current market price.
Stop Loss (SL): Set the stop-loss just below the 75-minute demand zone, introducing a slight buffer around 1180.
Target: Aim for levels below the 75-minute supply zone, approximately around 1215.
Entry Price: Consider entering at the current market price of 1194.
Why Lupin Presents an Opportunity 🌟:
Demand Zone Alignment: Lupin is strategically positioned in both the 75-minute and daily demand zones.
Trend Observation: The daily sideways trend, combined with proximity to the 20EMA, indicates favourable conditions for a potential bullish move.
Weekly Outlook: supply zone is very far on the weekly chart adds strength to the potential trade.
Final Trade Thoughts 🚀:
Lupin's current scenario isn't just an opportunity; it's a strategic move. With a keen focus on demand zones, and favourable weekly conditions, this trade deserves attention.
Trade Smart, Trade Confidently! 💹✨
Disclaimer 🚨:
This analysis is for educational purposes only. I am not a SEBI registered analyst. Trade responsibly.
LUPIN - Stock AnalysisLupin Ltd. is showing a strong technical and fundamental profile, making it an interesting prospect for investors.
From a technical perspective, the stock exhibits several "Strong Bullish" signals. The HighLow indicator suggests "Strong Bullish" sentiment, with the stock near a one-year high and likely to make a new high. The daily candlestick pattern reflects "Strong Bullish" sentiment, and the monthly candlestick pattern also displays "Strong Bullish" signals.
In terms of resistance, the stock has encountered medium-term resistance levels, with top points at 1200.0 on October 19, 2023, 1174.2 on October 3, 2023, and 1155.65 on September 14, 2023.
From a fundamental perspective, Lupin Ltd. has several positive attributes. The company's net profit has seen a significant turnaround, shifting from negative to positive, indicating an improved financial performance. The Piotroski F Score is at a stable value of 5.0, which suggests sound financial health.
Furthermore, the company's net profit has been consistently increasing for the last five quarters, and the same holds for Profit Before Tax, demonstrating strong operational performance. There has been steady growth in earnings per share (EPS) over the last four quarters.
Lupin Ltd. offers a very low dividend yield of 0.350%, indicating a preference for reinvesting profits for growth. Additionally, there is a short-term positive trend in total sales and net profit. The company has achieved annual sales growth for three consecutive years, and quarterly sales over the last five years are trending upward.
In summary, Lupin Ltd. presents a promising investment opportunity with strong technical and fundamental indicators. The stock's bullish technical signals, coupled with its improving financial performance and consistent growth, make it an attractive choice for investors seeking potential growth and value in the market. Nevertheless, investors should stay vigilant and monitor developments in both technical and fundamental aspects for a comprehensive understanding of the stock's potential.
Go Long above 1184.10
Stop Loss 1095
NSE:Lupin -trend change on card???
NSE:LUPIN
Lupin Limited is an India-based pharmaceutical company. The Company develops and commercializes a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in over 100 markets in the United States, India, South Africa, and across the Asia Pacific, Latin America, and others. It offers vitamins, minerals, supplements and neurological products. It has presence in the cardiovascular, dialectology, asthma, paediatrics, central nervous system, gastro-intestinal, anti-infectives and nonsteroidal anti-inflammatory drug therapy segments. Its complex generics portfolio includes Filgrastim, Peg-Filgrastim, Etanercept and Albuterol, and others. Its biosimilar products include Filgrastim, Peg-Filgrastim and Etanercept. Its specialty products consist of Solosec and NaMuscla. Its over-the-counter products include Softovac, Lupizyme, Aptivate, Lupisafe, Be One, V-Bath, and others. It supplies APIs for anti-retroviral, anti-malarial and others.
Disc: Invested, please do you own research
LUPIN--Bearish from 810 range??Observations::
the stock is trending upwards in daily time frame.
now the price is facing resistance @800 range.
If price breaks this resistance we have an immediate resistance @810 range.
now the stock is looking weak in buyside, if it will sustain above 800-810 range we will observe some bullish momentum again.
if price breaks 770 range we will observe fall till 740 range, keep track this instrument.
we have demand zone @700 range, will acts as support.
keep use alerts in this stock at respected levels.
#DIVISLAB #TORNTPHARM #ALKEM #AUROPHARMA #BIOCON #LUPIN #CIPLA #DIVISLAB
NSE: DIVISLAB
CMP: 3498
TP: 4200
SL: 3300
TF: <6m
RR > ~3.4 times
Return > 20%
THYROCARE CNXPHARMA LUPIN SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER BPLPHARMA MARKSANS BIOCON GRANULES IPCALAB LAURUSLABS NATCOPHARM GLAND ALKEM ZYDUSLIFE APOLLOHOSP FORTIS AARTIDRUGS ZYDUSWELL MAXHEALTH BAJAJHCARE
Factors:
BULLISH WEDGE BREAKOUT
Trend Following
Rising Volume with rising Prices.
Flag pattern breakout.
Pennant Pattern Breakout with Bullish Candle.
Retest Successful.
Higher Highs & Higher Lows.
Broken above RESISTANCE levels
Trading at SUPPORT levels
Earnings are strong.
Bullish Wedge Breakout
Risk Return Ratio is healthy.
And
Rising from Double Bottom Pattern to Flag Pattern forming.
If you like my work KINDLY LIKE SHARE & FOLLOW this page for free Stock Recommendations.
With 💚 from Rachit Sethia
#ASTERDM #BAJAJHCARE #MAXHEALTH #LAURUSLABS #NATCOPHARMA #GLAND #ASTERDM
NSE: ASTERDM
CMP: 225
TP: 300
SL: 200
TF: <6m
RR > ~3 times
Return > 33%
THYROCARE CNXPHARMA LUPIN SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER BPLPHARMA MARKSANS BIOCON GRANULES IPCALAB LAURUSLABS NATCOPHARM GLAND ALKEM ZYDUSLIFE APOLLOHOSP FORTIS AARTIDRUGS ZYDUSWELL MAXHEALTH BAJAJHCARE
Factors:
BULLISH WEDGE BREAKOUT
Trend Following
Rising Volume with rising Prices.
Flag pattern breakout.
Pennant Pattern Breakout with Bullish Candle.
Retest Successful.
Higher Highs & Higher Lows.
Broken above RESISTANCE levels
Trading at SUPPORT levels
Earnings are strong.
Bullish Wedge Breakout
Risk Return Ratio is healthy.
And
Rising from Double Bottom Pattern to Flag Pattern forming.
If you like my work KINDLY LIKE SHARE & FOLLOW this page for free Stock Recommendations.
With 💚 from Rachit Sethia
#BIOCON #LUPIN #DIVISLAB #ALKEM #IPCALAB #GRANULES #AUROPHARMA#BIOCON
NSE: BIOCON
CMP: 267
TP: 320
SL: 250
TF: <6m
RR > 4 times
Return > 20%
THYROCARE CNXPHARMA LUPIN NSE:CIPLA SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER BPLPHARMA MARKSANS BIOCON GRANULES IPCALAB LAURUSLABS NATCOPHARM GLAND ALKEM ZYDUSLIFE
Factors:
BULLISH WEDGE BREAKOUT
Trend Following
Rising Volume with rising Prices.
Flag pattern breakout.
Pennant Pattern Breakout with Bullish Candle.
Retest Successful.
Higher Highs & Higher Lows.
Broken above RESISTANCE levels
Trading at SUPPORT levels
Earnings are strong.
Bullish Wedge Breakout
Risk Return Ratio is healthy.
And
Rising from Double Bottom Pattern to Flag Pattern forming.
If you like my work KINDLY LIKE SHARE & FOLLOW this page for free Stock Recommendations.
With 💚 from Rachit Sethia
#AUROPHARMA #CIPLA #DIVISLAB #DRREDDY #LUPIN #GLENMARK #PFIZER #AUROPHARMA
NSE: AUROPHARMA
CMP: 437
TP: 535
SL: 400
TF: <6m
RR > 3.5 times
Return > 22%
THYROCARE CNXPHARMA LUPIN NSE:CIPLA SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER
Factors:
BULLISH WEDGE BREAKOUT
Trend Following
Rising Volume with rising Prices.
Flag pattern breakout.
Pennant Pattern Breakout with Bullish Candle.
Retest Successful.
Higher Highs & Higher Lows.
Broken above RESISTANCE levels
Trading at SUPPORT levels
Earnings are strong.
Bullish Wedge Breakout
Risk Return Ratio is healthy.
And
Rising from Double Bottom Pattern to Flag Pattern forming.
If you like my work KINDLY LIKE SHARE & FOLLOW this page for free Stock Recommendations.
With 💚 from Rachit Sethia